...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Why now?

Almost pooped my drawers when I fired up the screens this morning. My account balance had a mysterious drop. Go figure TD revalued the Zen shares from .85 down to .35. Phew.  I called and asked them to remove from my portfolio or give a value of 0.00. They could not do that and the only option was to transfer to a inactive account. So I told them open another account and I would send RVX over to keep Zen company. Hahahaha

CCD

Share
New Message
Please login to post a reply